Trevi Therapeutics (NASDAQ:TRVI) Given Buy Rating at D. Boral Capital

Trevi Therapeutics (NASDAQ:TRVI)‘s stock had its “buy” rating reissued by equities researchers at D. Boral Capital in a research note issued on Wednesday,Benzinga reports. They currently have a $21.00 price objective on the stock. D. Boral Capital’s price objective indicates a potential upside of 217.70% from the company’s current price.

TRVI has been the subject of several other research reports. Raymond James upgraded Trevi Therapeutics from an “outperform” rating to a “strong-buy” rating and boosted their price objective for the company from $9.00 to $29.00 in a research report on Monday, March 10th. Needham & Company LLC lowered their price objective on Trevi Therapeutics from $25.00 to $24.00 and set a “buy” rating for the company in a research report on Wednesday. Oppenheimer boosted their price objective on Trevi Therapeutics from $12.00 to $20.00 and gave the company an “outperform” rating in a research report on Tuesday, March 11th. Finally, HC Wainwright boosted their price objective on Trevi Therapeutics from $7.50 to $12.50 and gave the company a “buy” rating in a research report on Monday, March 10th. Seven equities research analysts have rated the stock with a buy rating and three have given a strong buy rating to the company. According to MarketBeat, the stock currently has a consensus rating of “Buy” and a consensus price target of $17.56.

Trevi Therapeutics Price Performance

NASDAQ:TRVI opened at $6.61 on Wednesday. The business has a 50 day moving average of $4.55 and a 200 day moving average of $3.73. The company has a market capitalization of $508.08 million, a price-to-earnings ratio of -15.02 and a beta of 0.90. Trevi Therapeutics has a 1-year low of $2.30 and a 1-year high of $7.39.

Trevi Therapeutics (NASDAQ:TRVI) last released its earnings results on Tuesday, March 18th. The company reported ($0.11) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.12) by $0.01. As a group, sell-side analysts anticipate that Trevi Therapeutics will post -0.49 EPS for the current year.

Insider Activity

In other news, insider Farrell Simon sold 81,313 shares of the business’s stock in a transaction that occurred on Monday, March 10th. The stock was sold at an average price of $6.75, for a total transaction of $548,862.75. Following the transaction, the insider now directly owns 76,900 shares of the company’s stock, valued at approximately $519,075. The trade was a 51.39 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Insiders own 24.37% of the company’s stock.

Hedge Funds Weigh In On Trevi Therapeutics

Hedge funds have recently made changes to their positions in the business. Summit Investment Advisors Inc. increased its stake in shares of Trevi Therapeutics by 84.2% during the fourth quarter. Summit Investment Advisors Inc. now owns 6,332 shares of the company’s stock valued at $26,000 after buying an additional 2,894 shares during the period. BNP Paribas Financial Markets grew its stake in Trevi Therapeutics by 130.9% in the third quarter. BNP Paribas Financial Markets now owns 11,930 shares of the company’s stock worth $40,000 after purchasing an additional 6,764 shares during the period. Raymond James Financial Inc. purchased a new stake in Trevi Therapeutics in the fourth quarter worth $49,000. Squarepoint Ops LLC purchased a new stake in Trevi Therapeutics in the fourth quarter worth $58,000. Finally, Two Sigma Advisers LP purchased a new stake in Trevi Therapeutics in the fourth quarter worth $66,000. 95.76% of the stock is owned by hedge funds and other institutional investors.

About Trevi Therapeutics

Trevi Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapy Haduvio for the treatment of chronic cough in idiopathic pulmonary fibrosis (IPF) and refractory chronic cough (RCC) conditions targeting the central and peripheral nervous systems.